Daily Market Reports | Oct 16 2025
This story features AUSSIE BROADBAND LIMITED, and other companies.
For more info SHARE ANALYSIS: ABB
The company is included in ASX200, ASX300 and ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
ABB ACE CSL D2O ELD EMR GMG IPD MM8 NWH PNR RMD SOM SRG
ABB AUSSIE BROADBAND LIMITED
Telecommunication – Overnight Price: $5.89
Canaccord Genuity rates ((ABB)) as Buy (1) –
Canaccord Genuity feels Aussie Broadband’s AGM update showed mixed conditions with softer trading before the September NBN speed upgrades offset by strong momentum since.
The broker highlights FY26 guidance for earnings (EBITDA) of $157-167m and capital expenditure of -$55-60m was maintained, broadly matching consensus. Subscriber additions of 19k are seen as modest, though growth has accelerated post-upgrade.
Canaccord highlights new Enterprise contracts, including Bakers Delight, and views the More/Tangerine deal as a key driver.
The broker retains a Buy rating and $6.85c target price.
This report was published on October 14, 2025.
Target price is $6.85 Current Price is $5.89 Difference: $0.96
If ABB meets the Canaccord Genuity target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $6.16, suggesting upside of 4.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 6.30 cents and EPS of 18.10 cents.
At the last closing share price the estimated dividend yield is 1.07%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 32.54.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 19.8, implying annual growth of 76.9%.
Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 29.7.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 10.60 cents and EPS of 26.50 cents.
At the last closing share price the estimated dividend yield is 1.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.23.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 26.4, implying annual growth of 33.3%.
Current consensus DPS estimate is 8.1, implying a prospective dividend yield of 1.4%.
Current consensus EPS estimate suggests the PER is 22.3.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ACE ACUSENSUS LIMITED
Transportation & Logistics – Overnight Price: $1.76
Canaccord Genuity rates ((ACE)) as Buy (1) –
Canaccord Genuity notes Acusensus has announced its largest US contract with a five-year US$23m program for automated workzone speed enforcement in Connecticut.
Post a long tender process, the company succeeded in beating the incumbent operator Verra Mobility, who operated the initial pilot program.
The analyst believes the contract reinforces Acusensus’ technology in the US market and sees further opportunities in other states where new legislation is now in place, including Kentucky, Michigan, and Vermont.
Target price is lifted higher to $2 from $1.65 and Buy rating remains unchanged. The analyst also lifts its revenue forecasts by 3% for FY27 and 7% for both FY27 and FY28.
This report was published on October 7, 2025.
Target price is $2.00 Current Price is $1.76 Difference: $0.24
If ACE meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 125.71.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 1760.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $216.45
Jarden rates ((CSL)) as Overweight (2) –
CSL reported the loss of a large NHS Ig contract, offset by a tender victory in Australia for Ig supply worth $1.1bn.
Jarden expects the pricing for this contract extension will be better than the original contract pricing negotiated pre-covid in 2020, and the volume may offer gross margin upside to Behring.
The biotech has also won a tender with the National Blood Authority to supply $73.6m of Idelvion over three years from July 2025.
Jarden highlights none of the tender wins are included in current forecasts, with the contract extension only at the end of September, but views there to be upside potential for management’s FY26 net profit after tax guidance in constant currency terms.
Target rises to $304.17 from $298.13. Overweight rating retained.
This report was published on October 13, 2025.
Target price is $304.17 Current Price is $216.45 Difference: $87.72
If CSL meets the Jarden target it will return approximately 41% (excluding dividends, fees and charges).
Current consensus price target is $275.39, suggesting upside of 27.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 366.31 cents and EPS of 846.79 cents.
At the last closing share price the estimated dividend yield is 1.69%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.56.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1114.6, implying annual growth of N/A.
Current consensus DPS estimate is 504.6, implying a prospective dividend yield of 2.3%.
Current consensus EPS estimate suggests the PER is 19.4.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 508.48 cents and EPS of 1130.66 cents.
At the last closing share price the estimated dividend yield is 2.35%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.14.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1255.0, implying annual growth of 12.6%.
Current consensus DPS estimate is 554.4, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 17.2.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
D2O DUXTON WATER LIMITED
Agriculture – Overnight Price: $1.53
Petra Capital rates ((D2O)) as Buy (1) –
Petra Capital scans across the latest winter rain updates, noting the winter period has failed to refill dam levels ahead of the season drawdown.
The robust snow season will provide some offset in terms of melt, but above-average rainfall is now required to lift dam levels, and the BOM has recently forecast a weak La Niña in spring.
Duxton Water continues to be well positioned to reap the benefits of ongoing dry conditions. The analyst proposes the company’s earnings and cash flow should benefit as Australia moves away from a period dominated by La Niñas.
Buy rating retained with a $2.08 target price.
This report was published on October 13, 2025.
Target price is $2.08 Current Price is $1.53 Difference: $0.55
If D2O meets the Petra Capital target it will return approximately 36% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY25:
Petra Capital forecasts a full year FY25 dividend of 7.40 cents and EPS of 18.40 cents.
At the last closing share price the estimated dividend yield is 4.84%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.32.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 7.70 cents and EPS of 10.00 cents.
At the last closing share price the estimated dividend yield is 5.03%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.30.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ELD ELDERS LIMITED
Agriculture – Overnight Price: $7.50
Canaccord Genuity rates ((ELD)) as Buy (1) –
Canaccord Genuity observes the latest Elders’ FY25 earnings guidance infers a consensus downgrade in earnings (EBIT) of -13%, which appears to have stemmed from a softer contribution from crop protection chemicals in the retail products segment.
Positively, trading conditions in the crop protection segment have since improved with better demand and lower discounting pressures from competing retailers.
The analyst believes the other segments for Elders are performing in line with expectations and is heartened by the inferred stronger cash flow conversion in 2H25.
The Delta acquisition will not be opposed, and Canaccord Genuity lowers its FY25 EPS forecast by -9% and -6% for FY26.
Target is lowered to $8.15 from $8.22. No change to Buy rating.
This report was published on October 9, 2025.
Target price is $8.15 Current Price is $7.50 Difference: $0.65
If ELD meets the Canaccord Genuity target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $8.80, suggesting upside of 17.3%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 36.00 cents and EPS of 48.90 cents.
At the last closing share price the estimated dividend yield is 4.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.34.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 43.7, implying annual growth of 54.9%.
Current consensus DPS estimate is 36.0, implying a prospective dividend yield of 4.8%.
Current consensus EPS estimate suggests the PER is 17.2.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 36.00 cents and EPS of 54.60 cents.
At the last closing share price the estimated dividend yield is 4.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.74.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 58.9, implying annual growth of 34.8%.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 12.7.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EMR EMERALD RESOURCES NL
Gold & Silver – Overnight Price: $5.27
Canaccord Genuity rates ((EMR)) as Buy (1) –
Emerald Resources updated production guidance for the 100%-owned Okvau Gold mine for the September quarter, which Canaccord Genuity views as “frustrating,” as it represents a third consecutive quarter where the Cambodian pit mine performs below guidance.
Management now expects guidance at around 22koz versus the analyst’s forecast of 25koz and previous guidance of 25-30koz, which is attributed to heavy wet weather that impacted access late in the quarter and delayed -5koz.
All-in-sustaining-costs for the quarter are estimated at US$1,150/oz against the prior Canaccord forecast of US$1,116/oz and guidance of US$900-US$1,000/oz.
FY26 production guidance remains unchanged at 105-120koz with all-in-sustaining-costs of US$966/oz, which meets mine-like expectations.
No change to Buy rating and $6 target.
This report was published on October 8, 2025.
Target price is $6.00 Current Price is $5.27 Difference: $0.73
If EMR meets the Canaccord Genuity target it will return approximately 14% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 38.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.87.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 9.00 cents and EPS of 50.00 cents.
At the last closing share price the estimated dividend yield is 1.71%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.54.
Market Sentiment: -1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GMG GOODMAN GROUP
Infra & Property Developers – Overnight Price: $32.89
Jarden rates ((GMG)) as Buy (1) –
Jarden believes the market is pricing in the broker’s most “bearish” outcome for Goodman Group, which is considered very conservative and assumes a decline of -5% in the group’s book value when logistics cap rates are starting to compress.
The market also appears to be discounting only $19.6bn of cumulative development profits over the next decade, against what the analyst expects to be at least $35-$40bn to be sourced from the data centre pipeline “alone.”
Management anticipates logistics to generate 30%-40% of the future development mix, inferring cumulative development profits could beat $35bn-$40bn again over the next decade.
Jarden’s bear case assumes management income will grow at a CAGR of 3.9% for FY26-FY29 versus a 21% CAGR achieved from FY15-FY25. Retain Buy with $41.10 target price.
This report was published on October 13, 2025.
Target price is $41.10 Current Price is $32.89 Difference: $8.21
If GMG meets the Jarden target it will return approximately 25% (excluding dividends, fees and charges).
Current consensus price target is $37.82, suggesting upside of 15.0%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 30.00 cents and EPS of 130.40 cents.
At the last closing share price the estimated dividend yield is 0.91%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.22.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 130.0, implying annual growth of 52.2%.
Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 25.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 30.00 cents and EPS of 146.70 cents.
At the last closing share price the estimated dividend yield is 0.91%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 143.3, implying annual growth of 10.2%.
Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 23.0.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
IPD IMPEDIMED LIMITED
Medical Equipment & Devices – Overnight Price: $0.04
Canaccord Genuity rates ((IPD)) as Speculative Buy (1) –
Canaccord Genuity retains a Speculative Buy rating and $0.07 target on ImpediMed while lowering forecasts by -30% to -40% for total contract win rates and revenue, respectively.
The broker assesses functional US reimbursement coverage for SOZO is now achieved at around 86% of covered lives, with Texas providing critical mass.
Sales deployment is the current constraint, with only 13 field roles and two business development staff supporting roll-out.
FY26 is expected to deliver steady development at fixed cost circa -$30m opex, delaying profitability and implying a $25m equity raise is expected by the analyst in FY27
Canaccord Genuity believes the reimbursement “hard parts” are complete and the opportunity now hinges on scaling the sales force.
This report was published on October 10, 2025.
Target price is $0.07 Current Price is $0.04 Difference: $0.028
If IPD meets the Canaccord Genuity target it will return approximately 67% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 4.20.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MM8 MEDALLION METAL LIMITED
Gold & Silver – Overnight Price: $0.54
Petra Capital rates ((MM8)) as Buy (1) –
Petra Capital raises its price target on Medallion Metals to $0.89 from $0.63 and maintains a Buy rating.
The broker notes leadership team strengthening with Tony James appointed COO and new directors David Kelly and Siobhan Pelliccia, alongside Stephen Moloney as Corporate Development Manager.
Key milestones include completion of the feasibility study and binding finance/offtake terms in Dec Q’25, with first production forecast for Mar Q’27.
Forecasts are upgraded on higher gold and copper price assumptions, driving FY27 EBITDA to $81.7m and NPAT to $53.8m.
This report was published on October 10, 2025.
Target price is $0.89 Current Price is $0.54 Difference: $0.355
If MM8 meets the Petra Capital target it will return approximately 66% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 35.67.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 7.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.95.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NWH NRW HOLDINGS LIMITED
Mining Sector Contracting – Overnight Price: $4.98
Canaccord Genuity rates ((NWH)) as Buy (1) –
Post completion of the Fredon acquisition, NRW Holdings has given a trading update which beat Canaccord Genuity’s expectations and points to a robust 1Q26 operating performance.
Against a positive mining macro backdrop, the company experienced better activity levels across all segments of the business as well as better weather in Qld.
FY26 guidance is for revenue over $4bn versus the analyst’s $4.1bn forecast and earnings (EBITDA) of $255m-$265m. At the midpoint, the new guidance infers a 4% earnings upgrade to the previous Canaccord estimate.
Buy rating maintained with a rise in the target price to $5.20 from $4.77. Although a material contract is concluding in FY27, the analyst points to a very strong pipeline.
This report was published on October 8, 2025.
Target price is $5.20 Current Price is $4.98 Difference: $0.22
If NWH meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $4.90, suggesting downside of -1.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 20.60 cents and EPS of 34.70 cents.
At the last closing share price the estimated dividend yield is 4.14%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.35.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.5, implying annual growth of 469.3%.
Current consensus DPS estimate is 19.5, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 14.4.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 22.40 cents and EPS of 37.90 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.14.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.8, implying annual growth of 9.6%.
Current consensus DPS estimate is 20.7, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 13.2.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PNR PANTORO GOLD LIMITED
Gold & Silver – Overnight Price: $6.20
Petra Capital rates ((PNR)) as Buy (1) –
Petra Capital re-iterates a Buy rating and $6.46 target price for Pantoro Gold, with no changes to forecasts.
The broker highlights a $55m FY26 exploration program at Scotia and OK underground mines, plus the first major regional drilling at Norseman in 30 years.
Drilling from the Bullen Decline at Central Mainfield has intersected all targeted structures, returning high-grade results such as 1.64m at 11.79g/t Au from Esperanto Reef.
First ore from Mainfield is forecast in FY27, lifting group output to 138koz from 103koz in FY26, with potential to exceed 175kozpa and reach 200kozpa at higher grades.
Spot gold assumptions would lift the target price to $8.80, the analyst adds.
This report was published on October 14, 2025.
Target price is $6.46 Current Price is $6.20 Difference: $0.26
If PNR meets the Petra Capital target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $5.99, suggesting downside of -3.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 58.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.63.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 65.8, implying annual growth of 7463.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 9.4.
Forecast for FY27:
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 84.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 69.9, implying annual growth of 6.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 8.9.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMD RESMED INC
Medical Equipment & Devices – Overnight Price: $41.61
Canaccord Genuity rates ((RMD)) as Buy (1) –
Canaccord Genuity continues to rate ResMed as a Buy with a $50 target price, with the pricing outlook considered the best the analyst has seen in a decade and scope for the gross margin to progress to 63% if optimisation programs are achieved.
The broker estimates 1Q26 non-GAAP EPS at around US$1.11, which is in line with consensus and represents 15% growth against FY25.
The enforced absence of Philips from the US market has lasted longer than anyone anticipated. The threat of return is likely to have held back the number 3, 4, and 5 players in the market from investing in manufacturing expansion, whereas ResMed scaled up immediately.
At this stage, Canaccord Genuity does not see Philips returning in any meaningful way and points to a slightly slower phase-in of gross margin improvements over the quarters. FY26 gross margin guidance stands at 61%-63%.
This report was published on October 10, 2025.
Target price is $50.00 Current Price is $41.61 Difference: $8.39
If RMD meets the Canaccord Genuity target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $49.07, suggesting upside of 17.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 38.11 cents and EPS of 170.63 cents.
At the last closing share price the estimated dividend yield is 0.92%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.39.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 170.7, implying annual growth of N/A.
Current consensus DPS estimate is 37.2, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 24.4.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 40.75 cents and EPS of 192.88 cents.
At the last closing share price the estimated dividend yield is 0.98%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.57.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 190.2, implying annual growth of 11.4%.
Current consensus DPS estimate is 40.0, implying a prospective dividend yield of 1.0%.
Current consensus EPS estimate suggests the PER is 21.9.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SOM SOMNOMED LIMITED
Medical Equipment & Devices – Overnight Price: $0.86
Canaccord Genuity rates ((SOM)) as Buy (1) –
Canaccord Genuity maintains a Buy rating and $1.00 target price on SomnoMed with no changes to forecasts, believing the stock remains the best medtech turnaround on the ASX in “living memory”.
Under new management, the broker highlights FY25 revenue of $111.5m, up 22% with $9.2m earnings (EBITDA), the first meaningful profit in its coverage history, supported by improved order fulfilment, US demand, and market share gains.
FY26 guidance of $119–126m revenue and $10–12m EBITDA is ahead of prior forecasts, with margin expansion expected as corporate and R&D costs stabilise.
RestAssure, a connected care initiative, is progressing at negligible incremental cost, offering potential to address US physician hesitancy towards oral appliance therapy.
This report was published on October 10, 2025.
Target price is $1.00 Current Price is $0.86 Difference: $0.14
If SOM meets the Canaccord Genuity target it will return approximately 16% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 78.18.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 57.33.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SRG SRG GLOBAL LIMITED
Mining Sector Contracting – Overnight Price: $2.61
Moelis rates ((SRG)) as Buy (1) –
SRG Global has acquired Total Tams Pty Ltd for $85m, pulling in an end-to-end diversified marine infrastructure services partner with a 25-year history.
Funding will consist of cash and debt of -$57.3m, and $27.7m in shares will be issued to the vendors, with a two-year earn-out opportunity.
Moelis upgrades its EPS estimates by 21% for FY26, 30% for FY27, and 32% for FY28, following management lifting earnings (EBITDA) guidance to at least $163m in FY26 with pro forma work in hand of $4.2bn and an opportunity pipeline of $11.5bn.
Buy rating retained. The analyst’s target price is lifted to $2.81 from $2.
This report was published on October 14, 2025.
Target price is $2.81 Current Price is $2.61 Difference: $0.2
If SRG meets the Moelis target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $2.92, suggesting upside of 11.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 7.10 cents and EPS of 11.40 cents.
At the last closing share price the estimated dividend yield is 2.72%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.89.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 13.2, implying annual growth of 64.2%.
Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 2.4%.
Current consensus EPS estimate suggests the PER is 19.8.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 8.40 cents and EPS of 13.60 cents.
At the last closing share price the estimated dividend yield is 3.22%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 15.1, implying annual growth of 14.4%.
Current consensus DPS estimate is 6.9, implying a prospective dividend yield of 2.6%.
Current consensus EPS estimate suggests the PER is 17.3.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: ABB - AUSSIE BROADBAND LIMITED
For more info SHARE ANALYSIS: ACE - ACUSENSUS LIMITED
For more info SHARE ANALYSIS: CSL - CSL LIMITED
For more info SHARE ANALYSIS: D2O - DUXTON WATER LIMITED
For more info SHARE ANALYSIS: ELD - ELDERS LIMITED
For more info SHARE ANALYSIS: EMR - EMERALD RESOURCES NL
For more info SHARE ANALYSIS: GMG - GOODMAN GROUP
For more info SHARE ANALYSIS: IPD - IMPEDIMED LIMITED
For more info SHARE ANALYSIS: MM8 - MEDALLION METAL LIMITED
For more info SHARE ANALYSIS: NWH - NRW HOLDINGS LIMITED
For more info SHARE ANALYSIS: PNR - PANTORO GOLD LIMITED
For more info SHARE ANALYSIS: RMD - RESMED INC
For more info SHARE ANALYSIS: SOM - SOMNOMED LIMITED
For more info SHARE ANALYSIS: SRG - SRG GLOBAL LIMITED